Cargando…

Comparing cystic fibrosis outcomes across the pond

Detalles Bibliográficos
Autores principales:	Taylor-Robinson, David C, Schechter, Michael S, Smyth, Rosalind L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2015
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345901/ https://www.ncbi.nlm.nih.gov/pubmed/25538210 http://dx.doi.org/10.1136/thoraxjnl-2014-206393

Ejemplares similares

Social Inequities and Cystic Fibrosis Outcomes: We Can Do Better
por: Oates, Gabriela R., et al.
Publicado: (2021)

The effect of social deprivation on clinical outcomes and the use of treatments in the UK cystic fibrosis population: a longitudinal study
por: Taylor-Robinson, David C, et al.
Publicado: (2013)

A Longitudinal Study of the Impact of Social Deprivation and Disease Severity on Employment Status in the UK Cystic Fibrosis Population
por: Taylor-Robinson, David C., et al.
Publicado: (2013)

Understanding the natural progression in %FEV(1) decline in patients with cystic fibrosis: a longitudinal study
por: Taylor-Robinson, David, et al.
Publicado: (2012)

Comparing the harmful effects of nontuberculous mycobacteria and Gram negative bacteria on lung function in patients with cystic fibrosis()
por: Qvist, Tavs, et al.
Publicado: (2016)

Low socioeconomic status is associated with worse lung function in the Danish cystic fibrosis population
por: Taylor-Robinson, David C., et al.
Publicado: (2014)

Cystic fibrosis revisited
por: Kulkarni, H, et al.
Publicado: (2019)

Early Antibiotics in Cystic Fibrosis: Lessons from the Cystic Fibrosis Pig Model
por: Lu, Shiping, et al.
Publicado: (2021)

Cystic Fibrosis Screen Positive, Inconclusive Diagnosis Genotypes in the Cystic Fibrosis Registry
por: Thompson, Cassandra, et al.
Publicado: (2023)

Clinical Advances in Cystic Fibrosis
por: Imperlini, Esther, et al.
Publicado: (2022)

Cystic Fibrosis: “Ionocyte Modulators”?
por: Shah, Viral S., et al.
Publicado: (2023)

The treatment burden of cystic fibrosis: a day-to-day experience with treatment as someone with cystic fibrosis
por: Maetz, Jessica, et al.
Publicado: (2021)

Evidence for Early Cystic Fibrosis Transmembrane Conductance Regulator Modulator Treatment for Children with Cystic Fibrosis Keeps Growing
por: Hoppe, Jordana E., et al.
Publicado: (2022)

Steps toward Cell Therapy for Cystic Fibrosis
por: Koh, Kyung Duk, et al.
Publicado: (2020)

A New Era for Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator Modulator Trials in Infants
por: Wainwright, Claire E.
Publicado: (2022)

Preclinical Modeling for Therapeutic Development in Cystic Fibrosis
por: Bonfield, Tracey L.
Publicado: (2020)

Dornase alpha use in patients with cystic fibrosis
por: Marostica, Paulo José C.
Publicado: (2013)

Cystic fibrosis in Brazil: achievements in survival
por: Vendrusculo, Fernanda Maria, et al.
Publicado: (2021)

The Impact of COVID-19 in Cystic Fibrosis
por: Flume, Patrick A., et al.
Publicado: (2022)

The Future of Highly Effective Modulator Therapy in Cystic Fibrosis
por: Daines, Cori L., et al.
Publicado: (2021)

New Developments in Cystic Fibrosis Airway Inflammation
por: Palaniyar, Nades, et al.
Publicado: (2015)

Ciprofloxacin dry powder inhaler in cystic fibrosis
por: Elborn, J Stuart
Publicado: (2016)

Cystic fibrosis-related diabetes: The unmet need
por: Pozo, Leonardo, et al.
Publicado: (2020)

Cystic Fibrosis Inflammation: Hyperinflammatory, Hypoinflammatory, or Both?
por: Murphy, Sean V., et al.
Publicado: (2019)

Where Is the Cystic Fibrosis Transmembrane Conductance Regulator?
por: Barbry, Pascal, et al.
Publicado: (2021)

Optimizing sexual and reproductive health across the lifespan in people with cystic fibrosis
por: West, Natalie E., et al.
Publicado: (2021)

Exercise Physiology Across the Lifespan in Cystic Fibrosis
por: Shei, Ren-Jay, et al.
Publicado: (2019)

A randomised controlled trial of rosuvastatin for the prevention of aminoglycoside-induced kidney toxicity in children with cystic fibrosis
por: McWilliam, Stephen J., et al.
Publicado: (2020)

Across the pond–lessons from the US on integrated healthcare
por: Fleury, Marie-Josée, et al.
Publicado: (2009)

Nutrition in Cystic Fibrosis: as important as the management of pulmonary disease
por: Adde, Fabíola Villac
Publicado: (2015)

Airway Inflammatory/Immune Responses in COPD and Cystic Fibrosis
por: De Rose, Virginia, et al.
Publicado: (2018)

Shifting Landscape of Airway Infection in Early Cystic Fibrosis
por: Hoppe, Jordana E., et al.
Publicado: (2019)

Editorial: Special Issue on “Therapeutic Approaches for Cystic Fibrosis”
por: Pedemonte, Nicoletta
Publicado: (2020)

Is PI3K a Villain in Cystic Fibrosis?
por: Natarajan, Viswanathan
Publicado: (2020)

Infection and Inflammation MUC up the Cystic Fibrosis Airway
por: Ma, Jonathan
Publicado: (2022)

Lung microbiota across age and disease stage in cystic fibrosis
por: Coburn, Bryan, et al.
Publicado: (2015)

Feasibility study to inform the design of a randomised controlled trial to eradicate Pseudomonas aeruginosa infection in individuals with Cystic Fibrosis
por: Hickey, Helen R, et al.
Publicado: (2010)

Urinary Biomarkers of Aminoglycoside-Induced Nephrotoxicity in Cystic Fibrosis: Kidney Injury Molecule-1 and Neutrophil Gelatinase-Associated Lipocalin
por: McWilliam, Stephen J., et al.
Publicado: (2018)

Cystic Fibrosis: A Disease in Transformation, yet More Work to Be Done!
por: Ramsey, Bonnie W., et al.
Publicado: (2022)

TMEM16A Potentiators: Is There a Need for New Modulators in Cystic Fibrosis?
por: Kim, Michael D., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h79164i6e1a9a6tb7vu0ljfevm